If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
200
results.
Updated on
14/09/2026 [06:52:00]
Results 175 to 200 of 200
Absstract of: EP4799638A1
Provided are an immunological adjuvant composition, a preparation method and use thereof. The immunological adjuvant composition comprises an immune activator and a liposome for loading the immune activator, wherein the immune activator includes a saponin and a CpG oligodeoxynucleotide. The immunological adjuvant composition is capable of eliciting an immune response against human herpesvirus and/or hepatitis B virus in a mammal and inducing a strong level of cellular immune response. By using the liposome to simultaneously load QS21 and the CpG oligodeoxynucleotide, the two components exhibit a favorable synergistic effect in promoting cellular immunity, and can induce a stronger level of cellular immune response compared to the commercially available vaccine Shingrix.
Absstract of: WO2025090565A1
Methods and compositions for rejuvenating and reprogramming stem cells are disclosed. The methods involve administering to a subject an ABCB5 targeted composition comprising an anti-ABCB5 antibody conjugated to a therapeutic payload comprised of an epigenetic reprogramming factor or a nucleic acid encoding an epigenetic reprogramming factor in an effective amount to reprogram and rejuvenate ABCB5+ stem cells in the subject. The compositions include anti-ABCB5 antibody conjugated to a therapeutic payload comprising an epigenetic reprogramming factor or a nucleic acid encoding an epigenetic reprogramming factor.
Absstract of: WO2025088192A1
The present invention provides for inventive means and methods for the coupling of di(alkyl)amines to polypeptides or peptides capable of forming a random coil conformation. The present invention further provides inventive compounds produced by the herein detailed methods, wherein said compounds are characterized by formula (I): A-B-bC-D. Said compounds comprise a polypeptide/peptide capable of forming a random coil conformation, an N-terminal protecting group, a di(alkyl)amino group, and optionally a linker. Furthermore, the present invention provides lipid nanoparticles comprising said compounds characterized by formula (I) as well as means and methods for the production of said lipid nanoparticles. Formulations comprising the inventive compounds and/or the lipid nanoparticles of the present invention are also provided. Further, the present invention also relates to uses of the inventive compounds, the lipid nanoparticles, and/or the formulations disclosed herein.
Absstract of: EP4800017A1
0001 The present invention relates to a novel ionizable lipid compound represented by Formula (I), or a salt thereof, and lipid nanoparticles comprising same. The lipid nanoparticles comprising the novel ionizable lipid compound, according to the present invention, have excellent nucleic acid encapsulation efficiency and high nucleic acid cell delivery efficiency.
Absstract of: WO2025089791A1
The present invention relates to a novel ionizable lipid compound represented by Formula (I) or a salt thereof, and a lipid nanoparticle containing the same. The lipid nanoparticle containing the novel ionizable lipid compound according to the present invention has an excellent nucleic acid encapsulation efficiency and has a high efficiency of cellular delivery of nucleic acid.
Absstract of: WO2025090663A1
The present disclosure provides novel polymer-conjugated lipids conjugated to a polyglycerol or a polyglycerol derivative. The present disclosure also provides lipid nanoparticles (LNPs) formulation using the polymer-conjugated lipids and methods of treating a disease by administering the LNP formulations, including multiple doses of the LNP formulations.
Absstract of: CN122664960A
本发明公开了一种超声调控外泌体纳米药物递送系统及其制备方法和应用，属于生物医药技术领域。该纳米药物递送系统包括载体、声敏剂和小干扰RNA，载体为肿瘤细胞经超声调控后分泌获得的超声调控外泌体（US‑Exo），声敏剂和小干扰RNA共同装载在US‑Exo上；制备方法包括对肿瘤细胞进行超声调控，收集细胞培养上清，分离和纯化，获得US‑Exo作为载体，小干扰RNA和声敏剂共同装载在US‑Exo上。本发明的纳米药物递送系统在超声辐照下能精准释放核酸药物和释放ROS杀伤肿瘤细胞，实现声动力治疗与基因沉默治疗的协同作用，可用于制备治疗结直肠癌肝转移的药物，具有重要的应用价值。
Absstract of: CN122669028A
本发明涉及生物医药递送技术领域，具体公开了一种靶向嗜酸性粒细胞的工程化外泌体制备方法及其制得的工程化外泌体。所述方法包括：提供外泌体供体细胞；构建包括 Siglec‑8 识别结构域、糖基化保护间隔臂和外泌体膜定位结构域的第一靶向模块；构建包括 CCR3 识别结构域和/或 IL‑5Rα 识别结构域的第二靶向模块；将编码第一靶向模块的核酸构建体导入供体细胞，并将第二靶向模块通过遗传工程方式或外泌体表面后修饰方式引入；培养供体细胞并收集培养上清；分离纯化外泌体；对外泌体进行 Siglec‑8 糖配体密度调控，获得靶向嗜酸性粒细胞的工程化外泌体。该工程化外泌体表面同时具有 Siglec‑8 识别能力以及 CCR3 和/或 IL‑5Rα 识别能力，可提高对嗜酸性粒细胞的靶向结合和递送选择性。
Absstract of: CN122664957A
本发明涉及生物医药、纳米药物递送及免疫调控技术领域，特别是涉及一种包载THL的靶向巨噬细胞脂质纳米颗粒及其制备方法与应用。将二甲氨丁酸二亚油甲酯、胆固醇、培化磷脂酰乙醇胺、磷脂酰丝氨酸和有机溶剂混合，将得到的混合液旋转蒸发成膜，得到脂质膜；将脂质膜水化，得到脂质体混悬液；将脂质体混悬液与焦碳酸二乙酯处理水混合、过滤，滤液为过滤脂质体混悬液；将过滤脂质体混悬液与Thiolutin溶液混合，离心得到的沉淀为包载THL的靶向巨噬细胞脂质纳米颗粒。本发明通过提高THL的巨噬细胞靶向富集能力及生物利用度，实现对因巨噬细胞BRISC过度激活导致的急性及慢性炎症性疾病的调控。
Absstract of: WO2025038642A1
Compositions and methods for editing, e.g., altering a DNA sequence, within a CD70 gene are provided. Compositions and methods for reducing or eliminating CD70 protein expression in a cell are provided. Compositions and methods for immunotherapy are provided.
Absstract of: WO2025036956A1
The present invention relates to compositions designed for localized delivery within a subject's body. More particularly, the invention pertains to therapeutic compositions that remain localized to specific organs or tissues and do not exhibit systemic distribution. These compositions include specific carriers and therapeutic agents suitable for various medical applications.
Absstract of: WO2025036455A1
The present invention relates to a drug delivery material and an application thereof. Specifically provided is a nanoparticle composition comprising a lipid component, the lipid component comprising a compound represented by formula (I). The nanoparticle composition of the present invention is delivered only at the site of administration.
Absstract of: US20250064897A1
A method of treating type-2 diabetes, chronic weight maintenance, or overindulgence conditions includes administering a pharmaceutically effective amount of a topical composition comprising a GLP-1 receptor agonist suspended in an anhydrous suspension base vehicle to an oral cavity of a subject for oral absorption therein. The topical composition is formulated to form a self-emulsifying liposome in an aqueous environment of the oral cavity.
Absstract of: WO2025076625A1
Provided is a glutamic or glutaric acid-based ionizable lipid compound of Formula (I) or a pharmaceutically acceptable salt thereof. The compound can be used to obtain lipid nanoparticles. In some embodiments, the lipid nanoparticle can comprise (a) from about 40 to about 100 mol % of the compound of Formula (I); (b) from 0 to about 20 mol % of a neutral lipid; (c) from 0 to about 50 mol % of a helper lipid; (d) from 0 to about 5 mol % of a polymer-conjugated lipid; and (e) from 0 to about 10 mol % of a hydrophobic component; wherein the mol % are based on the total lipids present in the nanoparticle. In some embodiments, the ionizable lipid compound is a glutamic acid-based ionizable lipid compound.
Absstract of: CN121868253A
The invention relates to a preparation method of an FZD1 active targeting nanoparticle. The preparation method comprises the following steps: S1, synthesizing DSPE-PEG2000-UM206 by using DSPE-PEG2000-COOH and a polypeptide UM206; and S2, synthesizing the FZD1 active targeting nanoparticles by using the polylactic acid-glycolic acid copolymer and the DSPE-PEG2000-UM206 (Distearoyl Phosphate Polyethylene Glycol 2000-UM206). Due to the adoption of the technical scheme, the FZD1 active targeting nanoparticles prepared by the preparation method of the FZD1 active targeting nanoparticles can promote the phagocytosis of osteosarcoma cells to the PLGA nanoparticles; the phagocytosis efficiency of osteosarcoma dry-like cells (OCSCs for short in subsequent description) on the FZD1 active targeting nanoparticles prepared by the preparation method of the FZD1 active targeting nanoparticles is high.
Absstract of: CN121910694A
The invention belongs to the technical field of biological medicine, and particularly relates to lipid nanoparticles, a preparation method thereof and application of the lipid nanoparticles in immune cell delivery. According to the invention, amino acid derived lipid is introduced as a fifth component on the basis of a preferable four-component formula. Through screening of the nitrogen-phosphorus ratio, the introduction proportion of the amino acid-derived lipid and the type of the amino acid-derived lipid, the novel lipid nanoparticles capable of efficiently delivering the primary immune cells are preferably selected. According to the delivery carrier, the delivery efficiency of primary immune cells, especially NK cells, can be remarkably improved, and a safe and efficient tool is provided for clinical application of immune cell engineering and immune cell treatment.
Absstract of: CN122664956A
本发明公开了一种铂修饰的钒酸铋纳米材料及其制备方法和应用。纳米材料包括钒酸铋（BiVO4）纳米颗粒、沉积在钒酸铋表面的铂（Pt）纳米颗粒以及包覆在最外层的表面功能化系统。本发明纳米材料不仅能通过光动力疗法直接诱导肿瘤细胞凋亡，还能触发免疫原性细胞死亡，释放损伤相关分子模式，从而促进树突状细胞成熟并激活全身性抗肿瘤T细胞免疫反应。本发明为解决肿瘤缺氧及免疫激活不足提供了新的治疗策略。
Absstract of: CN122664959A
本发明属于青蒿素应用技术领域，具体涉及一种带负电的青蒿素脂质纳米颗粒及其制备方法与应用。所述带负电的青蒿素脂质纳米颗粒，由青蒿素类药物、蛋黄卵磷脂和胆固醇按质量比5~15：60~80：5~25通过自组装得到。其中，所述青蒿素类药物为青蒿素、双氢青蒿素、青蒿琥酯、蒿甲醚或蒿乙醚中的任一种。所述青蒿素脂质纳米颗粒由位于外部的亲水结构与位于内部的疏水结构组成。所述蛋黄卵磷脂提供亲水结构，青蒿素类药物和胆固醇的混合物提供疏水结构。所述青蒿素脂质纳米颗粒的粒径为30nm~60nm，zeta电位为‑40mV~‑48mV。本发明的青蒿素脂质纳米颗粒可广泛应用于脱发疾病的治疗，尤其适用于雄激素性脱发，也可用于斑秃、产后脱发等其他类型的脱发。
Absstract of: CN122668972A
本发明公开了一种具有抗肠炎活性的sRNA分子及其应用。该sRNA分子的核苷酸序列如SEQ ID NO.1所示，源自肠道外致病性大肠杆菌的膜囊泡，通过上调BCL2表达、抑制MYD88/NF‑κB信号通路，发挥抑炎抑凋亡双重功能。负载该sRNA的口服结肠靶向纳米递送系统以介孔二氧化硅纳米颗粒为核心，依次经氨基化修饰负载sRNA，并进行透明质酸靶向修饰、聚乙二醇包裹及Eudragit S100肠溶包衣包裹。实验证实，该纳米递送系统能够显著改善结肠炎模型动物的临床症状和病理损伤，具有良好的生物相容性和治疗效果，可用于制备治疗炎症性肠病的药物。
Absstract of: CN122664868A
本发明涉及一种水溶性丝素蛋白富勒烯复合物及其制备方法和应用，属于富勒烯改性技术领域，用于解决现有的富勒烯改性方法多采用化学表面活性剂，生物安全性差；改性富勒烯的增殖作用弱、高温稳定性差的问题。包括以下步骤：将富勒烯、丝素蛋白和弱碱性助剂混合，进行球磨，得到第一混合粉体；向第一混合粉体中加入过氧化氢溶液，继续球磨，得到第二混合物料；向第二混合物料中加入水，经超声微流体均质机处理，得到悬浊液；将悬浊液离心，收集上层清液；将上层清液进行透析纯化，得到水溶性丝素蛋白富勒烯复合物水溶液。本发明的水溶性丝素蛋白富勒烯复合物水溶性好，有良好的生物安全性和抗氧化性，有良好的增殖作用和稳定性。
Absstract of: CN122668206A
本发明公开了一种仿生载肽脂质体及其制备方法和应用，属于生物医药技术领域。针对耗散自组装体在体内治疗时无法实现针对靶细胞作用的技术问题，本发明设计了具有耗散自组装功能的两亲性六肽nRIMSeIMSeE（nPMSe），在此基础上，进一步构建具有巨噬细胞靶向功能的仿生载nPMSe脂质体（nPMSe@LM）。仿生载肽脂质体nPMSe@LM可将nPMSe特异性递送至巨噬细胞内，通过耗散自组装以持续消除ROS，同时调节巨噬细胞表型并降低促炎细胞因子表达，解决了耗散自组装体在体内治疗时无法实现针对靶细胞作用的关键问题，实现对类风湿关节炎炎症缓解和关节组织修复的同步治疗。
Absstract of: CN122664963A
本发明属于医药技术领域，尤其涉及一种纳米颗粒及其制备方法和应用。本发明纳米颗粒的制备方法，包括以下步骤：称取COOH‑PEG‑PLGA、NHS、EDC和N,N‑二异丙基乙胺加入DMF中，活化COOH‑PEG‑PLGA，然后加入缀合物进行反应，得到改性PEG‑PLGA；将改性PEG‑PLGA、金丝桃苷和茵芋碱加入丙酮中，配制成油相溶液；将聚乙烯醇加入蒸馏水中，配制成水相溶液；将油相溶液加入水相溶液中，乳化得纳米颗粒。该纳米颗粒以改性PEG‑PLGA为载体，有效提高了金丝桃苷的包载率和心肌细胞靶向性。金丝桃苷与茵芋碱二者联用能够减少心肌缺血区域面积，降低心肌纤维化程度，并改善心功能。
Absstract of: CN122664962A
本发明属于生物医药技术领域，公开了一种纳米颗粒和包含纳米颗粒的囊泡递送系统及其制备方法和应用。所述纳米颗粒包括核心及包覆于核心表面的壳层；核心包括具有抗氧化活性的纳米酶，壳层包括多肽。所述囊泡递送系统包括细胞外囊泡和封装于所述细胞外囊泡内部的所述纳米颗粒。可选地，纳米颗粒还可包括包覆于壳层表面的多糖外壳层。本发明提供的纳米颗粒及囊泡递送系统能高效清除活性氧、恢复线粒体功能、逆转髓核细胞应激性衰老，并经体内外实验验证具有显著的抗炎、抗氧化、抗衰老及修复椎间盘结构的效果。
Absstract of: CN122664958A
本发明属于生物医药，具体涉一种靶向三阴性乳腺癌的核壳结构仿生纳米药物及其应用；本发明构建了一种核壳结构的仿生纳米药物递送系统AMT NPs，其以DNA四面体为内核、RAET杂化膜为外壳。该核壳结构平台通过RAET涂层与DNA四面体内核的协同整合，在激活抗肿瘤免疫应答的同时克服耐药性，并降低了载体自身的生物毒性，从而同时解决三阴性乳腺癌治疗中免疫原性缺失、免疫抑制微环境及多药耐药三大关键挑战，为精准癌症免疫治疗提供了新策略。
Nº publicación: BG114050A 31/08/2026
Applicant:
MEDITSINSKI UNIV \u2013 PLOVDIV [BG]
\u041C\u0435\u0434\u0438\u0446\u0438\u043D\u0441\u043A\u0438 \u0443\u043D\u0438\u0432\u0435\u0440\u0441\u0438\u0442\u0435\u0442 \u2013 \u041F\u043B\u043E\u0432\u0434\u0438\u0432
Absstract of: BG114050A
The present invention relates to a polymer system with a nano-in-micro architecture (fucoidan micromatrix with PLGA nanoparticles incorporated therein) and finds application as a system for controlled delivery of low molecular weight water-soluble medicinal substances (e.g. galantamine hydrobromide, benzydamine hydrochloride, betahistine hydrochloride, etc.). The system includes polylactic-co-glycolic acid (PLGA) nanoparticles in a fucoidan matrix, with the PLGA content being from 1% to 10% and fucoidan content being from 90% to 99% in the form of a fucoidan matrix with 100% PLGA nanoparticles incorporated therein, with the microparticles having an average diameter of 2 µm to 10 µm. The polymer system for controlled release of low molecular weight water-soluble drugs, when loaded with low molecular weight water-soluble drugs such as galantamine, benzydamine, doxylamine, contains polylactic-co-glycolic acid from 1% to 10% and fucoidan from 90% to 99% in the form of a fucoidan matrix with PLGA nanoparticles incorporated therein, in the form of a fucoidan matrix with PLGA nanoparticles incorporated therein from 94% to 99% and a low molecular weight water-soluble drug from 1% to 6%, wherein the microparticles have an average diameter of 2 µm to 10 µm.
BOPI
Electronic site
